A study found that high counts of CD68(+) macrophage were associated with improved progression-free survival (PFS) and OS for patients undergoing dose-dense chemoimmunotherapy, suggesting that macrophages may play a protective role in the TME of DLBCL (27). This evidence concerns the gene CD68 and diffuse large B-cell lymphoma.